Drug

LT3001 clinical trials

studies test it: 7
open now: 3
in phase 3: 0
first study started: 2020

Keep track of what changes. Save the LT3001 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

LT3001 Drug Product: 5
LT3001 Drug:high dose: 2

Studies by the year they started

7 studies that test it; most in 2022 (2)

Studies that test LT3001, by start year
Year	Studies
2020	1
2021	1
2022	2
2023	1
2026	2

By phase

A phase 1/2 study counts in both.

Phase 1: 1
Phase 2: 6

What it is tested for

Each study’s main condition, where its own words name it.

Ischemic Stroke: 7

Who runs them

Industry 7 · Other 0

Lumosa Therapeutics Co., Ltd. (5) · Shanghai Pharmaceuticals Holding Co., Ltd (2)

Studies

Open first, then newest update. How each study uses LT3001 is read from its arms, and is right about nine times in ten.

Testing it · 7

A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS ParticipantRecruitingPhase 2Lumosa Therapeutics Co., Ltd.NCT07890298Written as LT3001 Drug Product
A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic StrokeNot yet recruitingPhase 2Shanghai Pharmaceuticals Holding Co., LtdNCT07754825Written as LT3001 Drug:high dose
Efficacy and Safety of LT3001 on Treating the Acute Ischemic StrokeRecruitingPhase 2Shanghai Pharmaceuticals Holding Co., LtdNCT05686642Written as LT3001 Drug:high dose
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVTActive, not recruitingPhase 2Lumosa Therapeutics Co., Ltd.NCT05198323Written as LT3001 Drug Product
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy SubjectsCompletedPhase 1Lumosa Therapeutics Co., Ltd.NCT04809818Written as LT3001 drug product
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AISCompletedPhase 2Lumosa Therapeutics Co., Ltd.NCT04091945Written as LT3001 Drug Product
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS SubjectsCompletedPhase 2Lumosa Therapeutics Co., Ltd.NCT05403866Written as LT3001 Drug Product